TMO Beat-and-Raise: Thermo Fisher Posts 15% EPS Growth This Quarter

$TMO did something rare in this market: it made earnings look easy. Thermo Fisher Scientific just posted a beat-and-raise quarter with 6% organic revenue growth and 15% EPS growth, and the drivers are exactly what bulls have been waiting on. Strong pharma and biotech demand, a China recovery that nobody called, and semiconductor analysis tools all firing at once. Jim Cramer flagged it on his October 26 Mad Money broadcast, and for once, the hype has receipts.

The macro backdrop here actually matters. The 10-year Treasury yield is sitting at 5.0%, geopolitical noise from the Iran conflict is keeping the VIX elevated near 19.45, and investors are desperately hunting for earnings stories that don't come with an asterisk. TMO is one of the cleaner setups in the large-cap space right now: it sells the picks and shovels to the pharma, biotech, and semiconductor industries, which means it benefits whether your favorite drug trial wins or loses.

The bull case practically writes itself. Pharma capex is recovering after two years of post-COVID budget tightening. The Moderna-Merck personalized mRNA cancer vaccine (V940) showing a 42% improvement in recurrence-free survival at ESMO Madrid is exactly the kind of clinical momentum that translates into instrument orders and reagent demand for companies like TMO. More trials, more tools, more revenue. The China segment bouncing back adds another growth lever that was completely missing from estimates eighteen months ago.

The bear case is real though. At a beat-and-raise valuation, TMO isn't cheap. Cramer also raised a broader concern on the same broadcast: over $148 billion in IPOs and secondary offerings have hit the market this year, draining liquidity. Anthropic alone is targeting a $1.5 to $2 trillion valuation on its Nasdaq IPO under ticker $ANT, and Meta is raising up to $95 billion through equity offerings. That capital has to come from somewhere, and it often comes from rotating out of steady compounders like TMO into shiny new things.

Social sentiment on X is cautiously positive, leaning into the China recovery narrative and the biotech catalyst angle. YouTube financial commentary has been focused on AI and the Anthropic IPO buzz, which ironically means TMO is flying under the radar despite posting the kind of numbers that would have headlined every finance podcast in 2022.

If the market keeps rewarding companies that actually grow earnings while everything else debates whether a $2 trillion AI company deserves that price tag, TMO might be the most boring-exciting stock in your portfolio right now.